Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Filter results: >>>>

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	1.03	0.01	-0.588	1.0	1.02
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	1.03	0.01	-0.587	1.0	1.02
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.891	0.01	-0.351	1.0	0.919